FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies
VE Kennedy, CC Smith - Frontiers in Oncology, 2020 - frontiersin.org
The FLT3 receptor is overexpressed on the majority of acute myeloid leukemia (AML) blasts.
Mutations in FLT3 are the most common genetic alteration in AML, identified in …
Mutations in FLT3 are the most common genetic alteration in AML, identified in …
Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant
AH Bazarbachi, R Al Hamed, F Malard… - Therapeutic …, 2019 - journals.sagepub.com
FMS-like tyrosine kinase 3 (FLT3) mutations are one of the most frequently encountered
genetic alterations in acute myeloid leukemia (AML), and are generally associated with …
genetic alterations in acute myeloid leukemia (AML), and are generally associated with …
[HTML][HTML] Inhibition of FLT3: A Prototype for Molecular Targeted Therapy in Acute Myeloid Leukemia
MY Salman, JM Rowe, N Weigert - Engineering, 2021 - Elsevier
Modern therapy of acute myeloid leukemia (AML) began in 1973 with the first report of the
successful combination of daunorubicin and cytarabine, which led to complete remission in …
successful combination of daunorubicin and cytarabine, which led to complete remission in …
Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis
N Sly, K Gaspar - American Journal of Health-System Pharmacy, 2019 - academic.oup.com
Purpose This article reviews the pharmacology, efficacy, safety, cost, and future directions of
midostaurin for the treatment of acute myeloid leukemia (AML), aggressive systemic …
midostaurin for the treatment of acute myeloid leukemia (AML), aggressive systemic …